You are here: Industry Insights > vertex

News List

EC approves Vertex’s Symkevi for cystic fibrosis pharmaceutical-technology
November 05, 2018
The European Commission has approved London-based Vertex’s Symkevi (ivacaftor+tezacaftor) in combination with ivacaftor for patients with specific mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
FDA lifts clinical hold on gene therapy for sickle cell disease biospectrum
October 12, 2018
CRISPR and Vertex entered into a strategic research collaboration in 2015 aimed at the discovery and development of gene editing treatments using the CRISPR/Cas9 technology to correct defects in specific gene targets known to cause or contribute to partic
Vertex announces reimbursement agreement in Australia for ORKAMBI biospectrumasia
September 29, 2018
Australians with CF join thousands of patients worldwide who are already receiving lumacaftor/ivacaftor
Patients call for end to CF drug price row at key meeting pharmaphorum
September 27, 2018
Representatives of NHS England and cystic fibrosis drug company Vertex are to meet on Thursday to try and resolve a two-year impasse over access to life-changing medications.
Vertex and Genomics partner to use human genetics for precision medicines pharmaceutical-technology
September 03, 2018
Genomics’ analysis engine utilises genetics to understand human biology as well as the safety and efficacy of potential new drugs. The engine consists of more than 100 billion data points.
FDA allows use of Vertex’ Kalydeco in children aged under two pharmatimes
August 17, 2018
Use of Vertex Pharmaceuticals’ cystic fibrosis drug Kalydeco has been expanded in the US to include some children under the age of two.
MPs call on government to help with Orkambi debate pharmatimes
July 23, 2018
MPs are calling on NHS England and Vertex to come to an agreement over the price of cystic fibrosis drug Orkambi.
Vertex, NHS England no closer to Orkambi settlement pharmatimes
July 16, 2018
Vertex and NHS England remain locked in a battle over the provision of cystic fibrosis drug Orkambi, seemingly no closer to a settlement that would allow patients access to the drug on the NHS.
Vertex and NHS England reach impasse over cystic fibrosis drug price pharmaceutical-technology
July 12, 2018
Cystic fibrosis (CF)-focused Vertex has declared that its recent negotiations with NHS England regarding the price of its drug Orkambi (ivacaftor+lumacaftor) for CF have been inconclusive.
Vertex, NHS England no closer to Orkambi settlement pharmatimes
July 10, 2018
Vertex and NHS England remain locked in a battle over the provision of cystic fibrosis drug Orkambi, seemingly no closer to a settlement that would allow patients access to the drug on the NHS.

Previous page 1 2 3 4 5 6 7 Next page